Pharmacologic Perspectives of Functional Selectivity by the Angiotensin II Type 1 Receptor

Trends in Cardiovascular Medicine

Volumn 18, Issue 8, 2008, Pages 305-312

  Aplin, Mark ^a   Christensen, Gitte Lund ^a,b   Hansen, Jakob Lerche ^a  

^a DANISH NATIONAL RESEARCH FOUNDATION   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CELL MIGRATION; CELL REGENERATION; CELL SURVIVAL; DIABETIC NEPHROPATHY; DRUG SELECTIVITY; GENETIC TRANSCRIPTION; HEART CONTRACTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; METABOLIC REGULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOMEGALY; CARDIOVASCULAR DISEASES; FEASIBILITY STUDIES; GTP-BINDING PROTEINS; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 63449094061     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2009.01.003     Document Type: Review

References (53)

1. Ahn S., Shenoy S.K., Wei H., and Lefkowitz R.J. Differential kinetic and spatial patterns of b-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 279 (2004) 35518-35525
2. Ahuja P., Sdek P., and MacLellan W.R. Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol Rev 87 (2007) 521-544
3. Aplin M., Bonde M.M., and Hansen J.L. Molecular determinants of angiotensin II type 1 receptor functional selectivity. J Mol Cell Cardiol 46 (2009) 15-24
4. Aplin M., Christensen G.L., Schneider M., et al. The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and Langendorff-perfused hearts. Basic Clin Pharmacol Toxicol 100 (2007) 289-295
5. Aplin M., Christensen G.L., Schneider M., et al. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic Clin Pharmacol Toxicol 100 (2007) 296-301
6. Barnes W.G., Reiter E., Violin J.D., et al. b-Arrestin 1 and Gaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem 280 (2005) 8041-8050
7. D'Angelo D.D., Sakata Y., Lorenz J.N., et al. Transgenic Gaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 94 (1997) 8121-8126
8. Daniels D., Yee D.K., Faulconbridge L.F., and Fluharty S.J. Divergent behavioral roles of angiotensin receptor intracellular signaling cascades. Endocrinology 146 (2005) 5552-5560
9. DeWire S.M., Kim J., Whalen E.J., et al. Beta-arrestin-mediated signaling regulates protein synthesis. J Biol Chem 283 (2008) 10611-10620
10. Doan T.N., Ali M.S., and Bernstein K.E. Tyrosine kinase activation by the angiotensin II receptor in the absence of calcium signaling. J Biol Chem 276 (2001) 20954-20958
11. Drake M.T., Violin J.D., Whalen E.J., et al. Beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem 283 (2008) 5669-5676
12. Esposito G., Rapacciuolo A., Naga Prasad S.V., et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105 (2002) 85-92
13. Giacchetti G., Sechi L.A., Rilli S., and Carey R.M. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16 (2005) 120-126
14. Girnita L., Shenoy S.K., Sehat B., et al. b-Arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J Biol Chem 282 (2007) 11329-11338
15. Hansen J.L., Aplin M., Hansen J.T., et al. The human angiotensin AT(1) receptor supports G protein-independent extracellular signal-regulated kinase 1/2 activation and cellular proliferation. Eur J Pharmacol 590 (2008) 255-263
16. Harris D.M., Chen X., Pesant S., et al. Inhibition of angiotensin II Gq signaling augments beta-adrenergic receptor mediated effects in a renal artery stenosis model of high blood pressure. J Mol Cell Cardiol 46 (2009) 100-107
17. Holloway A.C., Qian H., Pipolo L., et al. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 61 (2002) 768-777
18. Hunton D.L., Barnes W.G., Kim J., et al. b-Arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol Pharmacol 67 (2005) 1229-1236
19. Hunyady L., and Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 20 (2006) 953-970
20. Kang J., Shi Y., Xiang B., et al. A nuclear function of b-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 123 (2005) 833-847
21. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4 (2005) 919-927
22. Kim J., Zhang L., Peppel K., et al. Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res 103 (2008) 70-79
23. Kohout T.A., Nicholas S.L., Perry S.J., et al. Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem 279 (2004) 23214-23222
24. Lambot M.A., Vermeylen D., and Noel J.C. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 357 (2001) 1619-1620
25. Lee M.H., El-Shewy H.M., Luttrell D.K., and Luttrell L.M. Role of ß-Arrestin-mediated Desensitization and Signaling in the Control of Angiotensin AT1a Receptor-stimulated Transcription. J Biol Chem 283 (2008) 2088-2097
26. Lee M.H., Song H.K., Ko G.J., et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. J Biol Chem 74 (2008) 890-900
27. Luttrell L.M. Composition and function of g protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity. J Mol Neurosci 26 (2005) 253-264
28. Lyngbaek S., Schneider M., Hansen J.L., and Sheikh S.P. Cardiac regeneration by resident stem and progenitor cells in the adult heart. Basic Res Cardiol 102 (2007) 101-114
29. Lyngso C., Erikstrup N., and Hansen J.L. Functional interactions between 7TM receptors in the Renin-Angiotensin System-Dimerization or crosstalk?. Mol Cell Endocrinol (2008)
30. Martini L., and Whistler J.L. The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 17 (2007) 556-564
31. McLachlan C.S., Ocsan R., Hambly B., and El Oakley R. Should an angiotensin-converting enzyme inhibitor be given at the time of reperfusion therapy in acute myocardial infarction. Am Heart J 156 (2008) e1
32. Mehta P.K., and Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292 (2007) C82-C97
33. Mifune M., Ohtsu H., Suzuki H., et al. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 280 (2005) 26592-26599
34. Motley E.D., Eguchi K., Gardner C., et al. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-a. Hypertension 41 (2003) 775-780
35. Noma T., Lemaire A., Naga Prasad S.V., et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117 (2007) 2445-2458
36. Piu F., Gauthier N.K., and Wang F. Beta-arrestin 2 modulates the activity of nuclear receptor RAR beta2 through activation of ERK2 kinase. Oncogene 25 (2006) 218-229
37. Rajagopal K., Whalen E.J., Violin J.D., et al. b-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A 103 (2006) 16284-16289
38. Revankar C.M., Vines C.M., Cimino D.F., and Prossnitz E.R. Arrestins block G protein-coupled receptor-mediated apoptosis. J Biol Chem 279 (2004) 24578-24584
39. Schmid C.L., Raehal K.M., and Bohn L.M. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A 105 (2008) 1079-1084
40. Scott RL: 2008. Angiotensin-converting enzyme inhibitor and/or angiotensin receptor antagonist for the postmyocardial infarction patient. Cardiol Clin 26:73--77, vii.
41. Smith N.J., Chan H.W., Osborne J.E., et al. Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy. Cell Mol Life Sci 61 (2004) 2695-2703
42. Stepan H., Faber R., Dornhofer N., et al. New insights into the biology of preeclampsia. Biol Reprod 74 (2006) 772-776
43. Swaminath G., Deupi X., Lee T.W., et al. Probing the b2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280 (2005) 22165-22171
44. Taniyama Y., Weber D.S., Rocic P., et al. Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates focal adhesions. Mol Cell Biol 23 (2003) 8019-8029
45. Tohgo A., Pierce K.L., Choy E.W., et al. b-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem 277 (2002) 9429-9436
46. Urban J.D., Clarke W.P., von Zastrow M., et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320 (2007) 1-13
47. Violin J.D., and Lefkowitz R.J. b-Arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28 (2007) 416-422
48. Wassmann S., and Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens Suppl 24 (2006) S15-S21
49. Wei H., Ahn S., Shenoy S.K., et al. Independent b-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A 100 (2003) 10782-10787
50. Weir M.R. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?. Clin Ther 29 (2007) 1803-1824
51. Wisler J.W., DeWire S.M., Whalen E.J., et al. A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A 104 (2007) 16657-16662
52. Xiao K., McClatchy D.B., Shukla A.K., et al. Functional specialization of b-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci U S A 104 (2007) 12011-12016
53. Zhai P., Yamamoto M., Galeotti J., et al. Cardiac-specific overexpression of AT1 receptor mutant lacking Gaq/Gai coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 115 (2005) 3045-3056